Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR001-203 Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia
2023-503770-21-00Phase 2Completed
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in 21-hydroxylase deficiency (21-OHD) comparing Tildacerfont arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in androstenedione after 12 weeks on treatment (Week 18). Started Jan 2021; status: completed.
02
Drugs
tildacerfont
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2023-503770-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503770-21-00.